Clinical trials: Traveler's Diarrhea
Diarrhea
Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E.
- Trial name
- NCT01067781
- Testing
- Heat-Labile Enterotoxin of E. coli (LT)
- Where
- 5 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Prevention of Travelers' Diarrhea
LT Vaccine Patch Self-Administration Study
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered…
- Trial name
- NCT00565461
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Prevention of Travelers' Diarrhea
Traveler's Diarrhea (TD) Automated Process
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
- Trial name
- NCT00751777
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Diarrhea
Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day…
- Trial name
- NCT02498418
- Testing
- Rifaximin, Xifaxan®
- Where
- United States
- Volunteers
- 739 people
- Sponsor
- Actavis Inc.
Travelers' Diarrhea
A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.
This study compared safety and efficacy of a generic rifaximin tablet to the reference listed drug in the treatment of travelers' diarrhea.
- Trial name
- NCT02920242
- Testing
- Rifaximin (Sandoz GmbH) tablet, Rifaximin (Xifaxan)
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Sandoz
Traveler's Diarrhea
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.
- Trial name
- NCT01142089
- Testing
- Rifamycin SV MMX
- Where
- 12 sites in Guatemala, Mexico
- Volunteers
- 264 people
- Sponsor
- Cosmo Technologies Ltd
Diarrhea, Travelers Diarrhea
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
This is a randomized, double-blind, placebo-controlled study to investigate a single daily dose of Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli…
- Conditions
- Diarrhea, Travelers Diarrhea, Infectious Diarrhea
- Trial name
- NCT05933525
- Testing
- Travelan
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Immuron Ltd.
Traveler's Diarrhea
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.
- Trial name
- ERASE (NCT01208922)
- Testing
- Rifamycin SV-MMX®, Ciprofloxacin
- Where
- 19 sites in Ecuador, Guatemala and 1 more
- Volunteers
- 835 people
- Sponsor
- Dr. Falk Pharma GmbH
Diarrhea Travelers, Antibiotic Resistant Infection
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among…
- Trial name
- NCT03535272
- Testing
- Bismuth subsalicylate
- Where
- United States
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention